Home › Medicare GLP-1 Bridge

Last reviewed Nov 5, 2026

The Medicare GLP-1 Bridge and the $50 price

We may earn a commission from some links on this page. How we make money.

Short answer: The Medicare GLP-1 Bridge is a Novo Nordisk access program that lets eligible Medicare beneficiaries with obesity get Wegovy for a $50 monthly copay. It launched July 1, 2026, runs nationwide through the end of 2027, and eligibility is determined by CMS. Your prescriber submits a prior authorization to start it.

How the Bridge works

Historically, Medicare didn't pay for weight-loss drugs. The GLP-1 Bridge is a manufacturer pathway that changes that for Wegovy specifically: eligible Medicare patients prescribed Wegovy for a covered FDA-approved indication pay $50 a month, where one month is a box of four pens or a bottle of 30 tablets.

Novo Nordisk describes it as "a new access pathway for millions of older adults living with obesity." The company notes that terms apply and it isn't a guarantee of coverage.

Who qualifies

  • Medicare beneficiaries living with obesity are the target group.
  • Coverage is limited to patients prescribed Wegovy for a covered FDA-approved indication.
  • Eligibility criteria are determined by CMS — not by this site, and not solely by Novo Nordisk.
  • Your pharmacy submits a prior authorization to CMS. Once approved, refills don't need a new prior authorization as long as you stay on the same GLP-1 medication.

Novo Nordisk hasn't published a public age or BMI cutoff for the Bridge; CMS sets the criteria. The most reliable way to find out if you qualify is to ask your prescriber to check and submit the prior authorization.

Does it cover the Wegovy pill?

The Bridge covers Wegovy, and Novo defines a covered month as "one box of four pens or one bottle of 30 tablets" — the tablet being the Wegovy pill (oral semaglutide). Confirm with your prescriber and pharmacy that the pill form is included for your situation, since program details can change.

How to start

  1. Talk to your own doctor about whether Wegovy fits your health profile.
  2. Ask them to prescribe it and to request the Bridge prior authorization through your pharmacy.
  3. Once CMS approves, you pay the $50 monthly copay at the pharmacy.

Most online weight-loss programs are a weak fit for Medicare patients — several don't serve them at all. For the Bridge, your own doctor is usually the simplest route. See what each program allows.

Wondering exactly what the $50 means for your Part D costs — deductible, out-of-pocket cap, Extra Help? See the full Medicare Part D GLP-1 cost breakdown.

The Bridge runs through the end of 2027. What happens to Medicare weight-loss coverage after that hasn't been announced.

Starting on Medicare

Ask your own doctor to prescribe Wegovy and request the Bridge prior authorization. Many online programs don't serve Medicare patients; see what each allows.

FAQ

What is the Medicare GLP-1 Bridge?

It's a Novo Nordisk access program, launched July 1, 2026, that lets eligible Medicare beneficiaries with obesity get Wegovy for a $50 monthly copay. It runs nationwide through the end of 2027, with eligibility determined by CMS.

Who qualifies for the $50 Wegovy price on Medicare?

Medicare beneficiaries living with obesity who are prescribed Wegovy for a covered FDA-approved indication. CMS determines the specific eligibility criteria. Your prescriber submits a prior authorization to start it.

Does the Medicare GLP-1 Bridge cover the Wegovy pill?

The Bridge covers Wegovy, and Novo Nordisk defines a covered month as a box of four pens or a bottle of 30 tablets — the tablet being the oral Wegovy pill. Confirm the pill form is included with your prescriber and pharmacy.

How long does the Medicare GLP-1 Bridge last?

Through the end of 2027. Novo Nordisk hasn't announced what happens after that.

Related guides

Sources